US Insurer United Rewards Amgen’s Early Entry With Bevacizumab And Trastuzumab

 
• By Aidan Fry

Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.

United_Healthcare
Major US health insurer UnitedHealthcare will soon prefer Amgen's becacizumab and trastuzumab biosimilars • Source: Shutterstock

More from Biosimilars

More from Products